shutterstock_728418391_casimiro_pt

casimiropt / Shutterstock.com

7 May 2019Big Pharma

English High Court invalidates Allergan glaucoma patent

One of Allergan’s patents has been invalidated after it was challenged by UK-based pharmaceutical companies Accord Healthcare and Aspire Pharma.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Allergan and tribe hit back at Mylan claims in SCOTUS brief

20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.

Federal Circuit sends Allergan’s patent dispute back to district court

18 March 2019 A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.

More on this story

Allergan and tribe hit back at Mylan claims in SCOTUS brief

20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.

Federal Circuit sends Allergan’s patent dispute back to district court

18 March 2019 A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.

More on this story

Allergan and tribe hit back at Mylan claims in SCOTUS brief

20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.

Federal Circuit sends Allergan’s patent dispute back to district court

18 March 2019 A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB